[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605795":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":20,"responsibleParty":41,"collaborators":11,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":11,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":11,"overallStatus":23,"whyStopped":11,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Women's Hospital School Of Medicine Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"chemotherapy group","EXPERIMENTAL",null,[13],"Drug: Camrelizumab combined with chemotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Camrelizumab combined with chemotherapy","Camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery",[9],[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Women's Hospital, School of Medicine, Zhejiang University","RECRUITING","Hangzhou","Zhejiang","310000","China","CN",{"type":30,"coordinates":31},"Point",[32,33],120.16142,30.29365,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Tingting Chen","CONTACT","86-13738102530","11318160@zju.edu.cn",{"type":42,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100605795","phase-2-chemo-immunotherapy-for-cervical-cancer-stage-iiicp-trial-100605795",false,"NCT07167160","Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial","Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;\n2. Positive PD-L1 expression;\n3. ECOG score ≤1\n\nExclusion Criteria:\n\n1. Positive parametrium or surgical margin;\n2. Incomplete radical surgery;\n3. Residual target lesions;\n4. Active autoimmune disease or autoimmune disease requiring systemic treatment;\n5. Previous treatment with immune checkpoint inhibitors.","FEMALE","18 Years","70 Years",{"count":54,"type":55},59,"ESTIMATED","INTERVENTIONAL",[58],"PHASE2","Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.",[61,62],"Cervical Cancer","Immunochemotherapy","2025-12-10",{"date":65,"type":66},"2025-12-18","ACTUAL",{"date":68,"type":66},"2025-03-10",{"date":70,"type":55},"2029-12-31",{"name":5,"class":6},1]